173 related articles for article (PubMed ID: 32891176)
1. Proteogenomic analysis of melanoma brain metastases from distinct anatomical sites identifies pathways of metastatic progression.
Taylor EM; Byrum SD; Edmondson JL; Wardell CP; Griffin BG; Shalin SC; Gokden M; Makhoul I; Tackett AJ; Rodriguez A
Acta Neuropathol Commun; 2020 Sep; 8(1):157. PubMed ID: 32891176
[TBL] [Abstract][Full Text] [Related]
2. DNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterations.
Marzese DM; Scolyer RA; Roqué M; Vargas-Roig LM; Huynh JL; Wilmott JS; Murali R; Buckland ME; Barkhoudarian G; Thompson JF; Morton DL; Kelly DF; Hoon DS
Neuro Oncol; 2014 Nov; 16(11):1499-509. PubMed ID: 24968695
[TBL] [Abstract][Full Text] [Related]
3. Novel treatments for melanoma brain metastases.
Kenchappa RS; Tran N; Rao NG; Smalley KS; Gibney GT; Sondak VK; Forsyth PA
Cancer Control; 2013 Oct; 20(4):298-306. PubMed ID: 24077406
[TBL] [Abstract][Full Text] [Related]
4. Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases.
Fischer GM; Jalali A; Kircher DA; Lee WC; McQuade JL; Haydu LE; Joon AY; Reuben A; de Macedo MP; Carapeto FCL; Yang C; Srivastava A; Ambati CR; Sreekumar A; Hudgens CW; Knighton B; Deng W; Ferguson SD; Tawbi HA; Glitza IC; Gershenwald JE; Vashisht Gopal YN; Hwu P; Huse JT; Wargo JA; Futreal PA; Putluri N; Lazar AJ; DeBerardinis RJ; Marszalek JR; Zhang J; Holmen SL; Tetzlaff MT; Davies MA
Cancer Discov; 2019 May; 9(5):628-645. PubMed ID: 30787016
[TBL] [Abstract][Full Text] [Related]
5. Pathologic and gene expression features of metastatic melanomas to the brain.
Hamilton R; Krauze M; Romkes M; Omolo B; Konstantinopoulos P; Reinhart T; Harasymczuk M; Wang Y; Lin Y; Ferrone S; Whiteside T; Bortoluzzi S; Werley J; Nukui T; Fallert-Junecko B; Kondziolka D; Ibrahim J; Becker D; Kirkwood J; Moschos S
Cancer; 2013 Aug; 119(15):2737-46. PubMed ID: 23695963
[TBL] [Abstract][Full Text] [Related]
6. Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES).
Lau PKH; Feran B; Smith L; Lasocki A; Molania R; Smith K; Weppler A; Angel C; Kee D; Bhave P; Lee B; Young RJ; Iravani A; Yeang HA; Vergara IA; Kok D; Drummond K; Neeson PJ; Sheppard KE; Papenfuss T; Solomon BJ; Sandhu S; McArthur GA
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34625515
[TBL] [Abstract][Full Text] [Related]
7. Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases.
Smalley I; Chen Z; Phadke M; Li J; Yu X; Wyatt C; Evernden B; Messina JL; Sarnaik A; Sondak VK; Zhang C; Law V; Tran N; Etame A; Macaulay RJB; Eroglu Z; Forsyth PA; Rodriguez PC; Chen YA; Smalley KSM
Clin Cancer Res; 2021 Jul; 27(14):4109-4125. PubMed ID: 34035069
[TBL] [Abstract][Full Text] [Related]
8. Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic Control.
Alvarez-Breckenridge C; Giobbie-Hurder A; Gill CM; Bertalan M; Stocking J; Kaplan A; Nayyar N; Lawrence DP; Flaherty KT; Shih HA; Oh K; Batchelor TT; Cahill DP; Sullivan R; Brastianos PK
Oncologist; 2019 May; 24(5):671-679. PubMed ID: 30796152
[TBL] [Abstract][Full Text] [Related]
9. Aquaporin-1 Protein Expression of the Primary Tumor May Predict Cerebral Progression of Cutaneous Melanoma.
Imrédi E; Liszkay G; Kenessey I; Plotár V; Gödény M; Tóth B; Fedorcsák I; Tímár J
Pathol Oncol Res; 2020 Jan; 26(1):405-410. PubMed ID: 30378011
[TBL] [Abstract][Full Text] [Related]
10. Proteogenomics of Malignant Melanoma Cell Lines: The Effect of Stringency of Exome Data Filtering on Variant Peptide Identification in Shotgun Proteomics.
Lobas AA; Pyatnitskiy MA; Chernobrovkin AL; Ilina IY; Karpov DS; Solovyeva EM; Kuznetsova KG; Ivanov MV; Lyssuk EY; Kliuchnikova AA; Voronko OE; Larin SS; Zubarev RA; Gorshkov MV; Moshkovskii SA
J Proteome Res; 2018 May; 17(5):1801-1811. PubMed ID: 29619825
[TBL] [Abstract][Full Text] [Related]
11. The Challenge of Classifying Metastatic Cell Properties by Molecular Profiling Exemplified with Cutaneous Melanoma Cells and Their Cerebral Metastasis from Patient Derived Mouse Xenografts.
Neuditschko B; Janker L; Niederstaetter L; Brunmair J; Krivanek K; Izraely S; Sagi-Assif O; Meshel T; Keppler BK; Del Favero G; Witz IP; Gerner C
Mol Cell Proteomics; 2020 Mar; 19(3):478-489. PubMed ID: 31892524
[TBL] [Abstract][Full Text] [Related]
12. Patterns of disease control and survival in patients with melanoma brain metastases undergoing immune-checkpoint blockade.
Milsch L; Gesierich A; Kreft S; Livingstone E; Zimmer L; Goebeler M; Schadendorf D; Schilling B
Eur J Cancer; 2018 Aug; 99():58-65. PubMed ID: 29906735
[TBL] [Abstract][Full Text] [Related]
13. Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities?
Gampa G; Vaidhyanathan S; Sarkaria JN; Elmquist WF
Pharmacol Res; 2017 Sep; 123():10-25. PubMed ID: 28634084
[TBL] [Abstract][Full Text] [Related]
14. Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis.
Marzese DM; Scolyer RA; Huynh JL; Huang SK; Hirose H; Chong KK; Kiyohara E; Wang J; Kawas NP; Donovan NC; Hata K; Wilmott JS; Murali R; Buckland ME; Shivalingam B; Thompson JF; Morton DL; Kelly DF; Hoon DS
Hum Mol Genet; 2014 Jan; 23(1):226-38. PubMed ID: 24014427
[TBL] [Abstract][Full Text] [Related]
15. Distinct genetic profiles of extracranial and intracranial acral melanoma metastases.
Sharma G; Lian CG; Lin WM; Amin-Mansour A; Jané-Valbuena J; Garraway L; Bao W; Yoon CH; Ibrahim N
J Cutan Pathol; 2016 Oct; 43(10):884-91. PubMed ID: 27251777
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy.
Ahmed KA; Abuodeh YA; Echevarria MI; Arrington JA; Stallworth DG; Hogue C; Naghavi AO; Kim S; Kim Y; Patel BG; Sarangkasiri S; Johnstone PA; Sahebjam S; Khushalani NI; Forsyth PA; Harrison LB; Yu M; Etame AB; Caudell JJ
Ann Oncol; 2016 Dec; 27(12):2288-2294. PubMed ID: 27637745
[TBL] [Abstract][Full Text] [Related]
17. The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases: The implications for BRAF inhibitor therapy.
Hannan EJ; O'Leary DP; MacNally SP; Kay EW; Farrell MA; Morris PG; Power CP; Hill ADK
Medicine (Baltimore); 2017 Dec; 96(48):e8404. PubMed ID: 29310328
[TBL] [Abstract][Full Text] [Related]
18. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.
Dummer R; Goldinger SM; Turtschi CP; Eggmann NB; Michielin O; Mitchell L; Veronese L; Hilfiker PR; Felderer L; Rinderknecht JD
Eur J Cancer; 2014 Feb; 50(3):611-21. PubMed ID: 24295639
[TBL] [Abstract][Full Text] [Related]
19. The use of systemic therapies for the treatment of brain metastases in metastatic melanoma: opportunities and unanswered questions.
Murrell J; Board R
Cancer Treat Rev; 2013 Dec; 39(8):833-8. PubMed ID: 23845462
[TBL] [Abstract][Full Text] [Related]
20. Brain metastasis is predetermined in early stages of cutaneous melanoma by CD44v6 expression through epigenetic regulation of the spliceosome.
Marzese DM; Liu M; Huynh JL; Hirose H; Donovan NC; Huynh KT; Kiyohara E; Chong K; Cheng D; Tanaka R; Wang J; Morton DL; Barkhoudarian G; Kelly DF; Hoon DS
Pigment Cell Melanoma Res; 2015 Jan; 28(1):82-93. PubMed ID: 25169209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
